Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Memantine (Primary)
- Indications Down syndrome
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 14 Apr 2017 Planned End Date changed from 1 Jul 2018 to 1 Mar 2019.
- 14 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.